The U.S. Food and Drug Administration (FDA) has approved Polarean's Xenoview, a drug-device combination that uses xenon-129 (Xe-129) gas with MRI to visualize and quantify regional lung function.
Xenoview is a hyperpolarized Xe-129 gas contrast agent indicated for use with MRI for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. The product has not been evaluated for use with lung perfusion imaging.
Xenoview is the first and only inhaled MRI hyperpolarized contrast agent for novel visualization of lung ventilation, Polarean noted.
